Epigene Labs ensures cancer drug hunters pilot R&D programs thanks to rich and diverse human genomic data. The company’s technology platform combines artificial intelligence with domain expertise for the aggregation and analysis of multi-dimensional genomic data.
The team initially focuses on the identification of immunotherapy drug targets and biomarkers based on gene expression datasets from multiple public and private databases. Epigene Labs thus aspires to significantly accelerate drug discovery for precision medicine in oncology.
The company is supported by Station F, Agoranov, Cancer Campus, AstraZeneca, and the Harvard Innovation Labs.